• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

    6.125 +0.275 (+4.70%)
    Streaming Delayed Price Updated: 12:23 PM EDT, Jul 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 607,203
    Open 5.910
    Bid (Size) 6.150 (500)
    Ask (Size) 6.220 (100)
    Prev. Close 5.850
    Today's Range 5.500 - 6.240
    52wk Range 4.800 - 13.69
    Shares Outstanding 42,940,089
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Monday's after hours session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
    From Aligos Therapeutics
    Via GlobeNewswire

    Performance

    YTD
    -32.9%
    -32.9%
    1 Month
    +23.5%
    +23.5%
    3 Month
    -24.3%
    -24.3%
    6 Month
    -27.2%
    -27.2%
    1 Year
    -18.3%
    -18.3%

    More News

    Read More
    News headline image
    Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics (NASDAQ:ALGS) Surges After Hours on Q1 Earnings Beat ↗
    Via Chartmill
    Aligos Therapeutics Inc (NASDAQ:ALGS) Reports Q4 Revenue Miss, Highlights 2026 Clinical Catalysts ↗
    Via Chartmill
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Presents Positive Data at HEP-DART 2025
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics to Present at Upcoming Investor Conferences
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
    From Aligos Therapeutics
    Via GlobeNewswire

    Frequently Asked Questions

    Is Aligos Therapeutics, Inc. - Common stock publicly traded?
    Yes, Aligos Therapeutics, Inc. - Common stock is publicly traded.
    What exchange does Aligos Therapeutics, Inc. - Common stock trade on?
    Aligos Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Aligos Therapeutics, Inc. - Common stock?
    The ticker symbol for Aligos Therapeutics, Inc. - Common stock is ALGS on the Nasdaq Stock Market
    What is the current price of Aligos Therapeutics, Inc. - Common stock?
    The current price of Aligos Therapeutics, Inc. - Common stock is 6.125
    When was Aligos Therapeutics, Inc. - Common stock last traded?
    The last trade of Aligos Therapeutics, Inc. - Common stock was at 07/07/26 12:23 PM ET
    What is the market capitalization of Aligos Therapeutics, Inc. - Common stock?
    The market capitalization of Aligos Therapeutics, Inc. - Common stock is 263.01M
    How many shares of Aligos Therapeutics, Inc. - Common stock are outstanding?
    Aligos Therapeutics, Inc. - Common stock has 263M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.